MGD011: Phase I started

Johnson & Johnson’s Janssen Biotech Inc. unit began an open-label, dose-escalation, dose-expansion, international Phase I trial to evaluate IV MGD011, starting at a 0.5 ng/kg dose, in about 140 patien...